Patel Sanj K 4

What Happened Sanj K. Patel, Chairman, CEO and a director of Kiniksa Pharmaceuticals (KNSA), reported conversion of derivative securities on June 1, 2026. The Form 4 shows 900,000 shares acquired via conversion and a corresponding disposition of 900,000 derivative securities at $0.00 — indicating the derivative instruments were converted into ordinary shares with no cash proceeds. This was a conversion of holdings, not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-01 (reported on Form 4 filed 2026-06-02 — timely filing)
• Action: Conversion of derivative security (transaction code C)
• Quantity: 900,000 shares acquired; 900,000 derivative securities disposed
• Price/value: Acquisition price listed as N/A; disposition reported at $0.00 — no cash changed hands
• Shares owned after transaction: Not stated in the filing
• Footnote: Each Class B ordinary share is convertible (at holder’s election) into Class A or Class B1 shares and converts automatically on transfer to an unaffiliated party (per footnote F1)

Context This filing reflects a conversion of convertible securities into ordinary shares (a structural reclassification), not a market sale or purchase. Conversions like this are typically administrative and do not by themselves imply buying or selling intent.